[go: up one dir, main page]

WO2024211360A3 - Agents d'inversion spécifiques pour traiter la toxicité aiguë et chronique de fentanyls - Google Patents

Agents d'inversion spécifiques pour traiter la toxicité aiguë et chronique de fentanyls Download PDF

Info

Publication number
WO2024211360A3
WO2024211360A3 PCT/US2024/022762 US2024022762W WO2024211360A3 WO 2024211360 A3 WO2024211360 A3 WO 2024211360A3 US 2024022762 W US2024022762 W US 2024022762W WO 2024211360 A3 WO2024211360 A3 WO 2024211360A3
Authority
WO
WIPO (PCT)
Prior art keywords
fentanyls
chronic toxicity
treat acute
reversal agents
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2024/022762
Other languages
English (en)
Other versions
WO2024211360A2 (fr
Inventor
Yan Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Virginia Commonwealth University
Original Assignee
Virginia Commonwealth University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Commonwealth University filed Critical Virginia Commonwealth University
Publication of WO2024211360A2 publication Critical patent/WO2024211360A2/fr
Publication of WO2024211360A3 publication Critical patent/WO2024211360A3/fr
Anticipated expiration legal-status Critical
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des antagonistes du récepteur opioïde Mu (MOR) qui inversent spécifiquement et efficacement la toxicité aiguë et chronique du fentanyl et de ses analogues. Les antagonistes ont été développés en modifiant le squelette structural du fentanyl et/ou du phénylfentanil. Les antagonistes entrent en compétition avec les fentanyls au niveau du site de liaison MOR et, lorsqu'ils sont liés, ils inversent la toxicité des fentanyls de manière plus efficace et sélective que la naloxone, la naltrexone et d'autres opioïdes de type époxymorphinane.
PCT/US2024/022762 2023-04-04 2024-04-03 Agents d'inversion spécifiques pour traiter la toxicité aiguë et chronique de fentanyls Pending WO2024211360A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363456837P 2023-04-04 2023-04-04
US63/456,837 2023-04-04

Publications (2)

Publication Number Publication Date
WO2024211360A2 WO2024211360A2 (fr) 2024-10-10
WO2024211360A3 true WO2024211360A3 (fr) 2025-01-16

Family

ID=92972822

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/022762 Pending WO2024211360A2 (fr) 2023-04-04 2024-04-03 Agents d'inversion spécifiques pour traiter la toxicité aiguë et chronique de fentanyls

Country Status (1)

Country Link
WO (1) WO2024211360A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021159993A1 (fr) * 2020-02-14 2021-08-19 Pharmablock Sciences (Nanjing) , Inc. Inhibiteurs de la kinase associée au récepteur de l'interleukine 1 (irak)/tyrosine kinase du récepteur de type fms (flt3), leurs produits pharmaceutiques et leurs procédés
US20220390439A1 (en) * 2019-10-21 2022-12-08 Veriteque Usa, Inc. Fentanyl analogue detection methods and kits thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220390439A1 (en) * 2019-10-21 2022-12-08 Veriteque Usa, Inc. Fentanyl analogue detection methods and kits thereof
WO2021159993A1 (fr) * 2020-02-14 2021-08-19 Pharmablock Sciences (Nanjing) , Inc. Inhibiteurs de la kinase associée au récepteur de l'interleukine 1 (irak)/tyrosine kinase du récepteur de type fms (flt3), leurs produits pharmaceutiques et leurs procédés

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DOSEN-MICOVIC LJILJANA: "Molecular modeling of fentanyl analogs", JOURNAL OF THE SERBIAN CHEMICAL SOCIETY, SERBIAN CHEMICAL SOCIETY, BELGRADE, vol. 69, no. 11, 1 January 2004 (2004-01-01), Belgrade , pages 843 - 854, XP093267656, ISSN: 0352-5139, DOI: 10.2298/JSC0411843D *
GARCÍA MÓNICA, VIRGILI MARINA, ALONSO MÒNICA, ALEGRET CARLES, FERNÁNDEZ BEGOÑA, PORT ADRIANA, PASCUAL ROSALÍA, MONROY XAVIER, VIDA: "4-Aryl-1-oxa-4,9-diazaspiro[5.5]undecane Derivatives as Dual μ-Opioid Receptor Agonists and σ 1 Receptor Antagonists for the Treatment of Pain", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 63, no. 5, 12 March 2020 (2020-03-12), US , pages 2434 - 2454, XP093267655, ISSN: 0022-2623, DOI: 10.1021/acs.jmedchem.9b01256 *

Also Published As

Publication number Publication date
WO2024211360A2 (fr) 2024-10-10

Similar Documents

Publication Publication Date Title
BRPI0518581A2 (pt) compostos de cromanilurÉia que inibem o receptor do subtipo 1 do recepetor vanilàide (vr1) e usos destes
IL193690A0 (en) 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists
WO2007120864A3 (fr) Compositions et procedes permettant d'augmenter la puissance analgesique de composes lies par liaison covalente, d'attenuer leurs effets secondaires defavorables et d'empecher leur utilisation abusive
MX2020002968A (es) Moduladores selectivos de p2x3.
WO2007027734A3 (fr) Heterocycles d'azote pontes et bicycliques
MX2010014232A (es) Compuesto de sulfamida o sal del mismo.
WO2007061739A3 (fr) Compositions pharmaceutiques
Todd et al. Effect of premedication on drug absorption and gastric emptying
WO2006042102A3 (fr) Composes de pyrrolo-pyridine, de pyrrolo-pyrimidine et composes heterocycliques apparentes
WO2008020405A3 (fr) Composés d'azétidine
WO2008005345A3 (fr) Compositions d'antagonistes de 5-ht3 et d'antagonistes de dopamine d2 pour le traitement d'états chroniques associés à la dopamine
CO6341547A2 (es) Uso de antagonistas opioides para el tratamiento de retencion urinaria
WO2007122581A3 (fr) Compositions et kits utiles dans le traitement de maladies respiratoires
WO2007111945A3 (fr) Procede de gestion therapeutique de la diarrhee
EP2286817A3 (fr) Méthode de traitement des troubles intestinaux fonctionnels
BRPI0815797A2 (pt) Compostos 8-azabiciclo[3.2.1]octil-2-hidroxibanzamida como antagonistas de receptor opióide mu
WO2004082623A3 (fr) Composes piperidine substituee
WO2008002946A3 (fr) Procédé permettant de moduler la croissance de neurites à l'aide d'un antagoniste du récepteur de la galanine de type 3
WO2005110416A3 (fr) 2-arylpyrimidines disubstituees en 4,5
WO2024211360A3 (fr) Agents d'inversion spécifiques pour traiter la toxicité aiguë et chronique de fentanyls
MX2012011216A (es) Antagonista del receptor opioide para usarse en el tratamiento de la enfermedad herpes zóster.
WO2008103185A3 (fr) Carboxamides substitués
WO2009076408A3 (fr) Dérivés de 3-carboxypropyl-aminotétraline et composés associés en tant qu'antagonistes du récepteurs mu-opioïde
WO2008101219A3 (fr) Compositions et procédés d'inhibition ou d'inversion de troubles fibrotiques
WO2007014263A3 (fr) Composes d'octahydroisoquinoleine comme modulateurs de recepteurs opioides

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24785665

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2024785665

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2024785665

Country of ref document: EP

Effective date: 20251104